143090-92-0

143090-92-0 structure

Name: ANAKINRA
Chemical Name: ANAKINRA
CAS Number: 143090-92-0
Molecular Formula: C₇₅₉H₁₁₈₆N₂₀₈O₂₃₂S₁₀
Molecular Weight: 509.556
Catalog: Research Areas Cancer
Create Date: 2018-01-13 04:44:29
Modify Date: 2025-08-25 10:04:17
Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Anakinra is the first biological agent to block the pro-inflammatory effects[1][2].

Name	ANAKINRA
Synonyms	(7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-({[(2,2-dimethylpropanoyl)oxy]methoxy}imino)acetyl]amino}-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-[[(2,2-dimethyl-1-oxopropoxy)methoxy]imino]-1-oxoethyl]amino]-3-ethenyl-8-oxo-, (7R)-

Description	Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Anakinra is the first biological agent to block the pro-inflammatory effects[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
Target	IL-1R[1].
In Vivo	Combined etanercept (5 mg/kg, ip) and Anakinra (100 mg/kg, I.P. daily for 7 days) substantially improves marginal mass human islet engraftment in immunodeficient mice[2]. Anakinra enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan[3].
References	[1]. Cvetkovic RS, et al. Anakinra. BioDrugs. 2002;16(4):303-11; discussion 313-4. [2]. McCall M, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant. 2012 Feb;12(2):322-9. [3]. Harnack U, et al. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan. Anticancer Res. 2010 Oct;30(10):3959-65.